The phase 1/2 MajesTEC-1 study was designed to assess the use of teclistamab, a B-cell maturation antigen bispecific antibody, in the treatment of patients with triple-class-exposed relapsed or refractory multiple myeloma (RRMM). The enrolment period overlapped with the period of peak infection and death during the COVID-19 pandemic. RRMM is associated with a particularly high risk of infection, and MajesTEC-1 participants had many of the features identified as risk factors for COVID-19 morbidity and mortality. The aim of this analysis was to determine the impact of COVID-19 on the outcomes of patients treated with teclistamab in MajesTEC-1.

Chimeric antigen receptor (CAR) T-cell therapy is an effective treatment for patients with relapsed or refractory multiple myeloma (RRMM), but most patients ultimately relapse on the currently approved agents, which target B-cell maturation antigen (BCMA). MCARH109 is a first-in-class CAR T-cell therapy that targets an alternative myeloma antigen, GPRC5D (G-protein-coupled receptor, class C, group 5, member D). The aim of this study was to investigate responses, toxicities and immune profiles in patients with RRMM receiving MCARH109.

Multiple myeloma often becomes refractory to the three main classes of treatment. Therefore, treatments that use different mechanisms of action and induce deep, durable remission are required. Linvoseltamab is a fully human B-cell maturation antigen × CD3 bispecific antibody that has shown promising antitumour activity in preclinical studies. The aim of this study was to assess the efficacy and safety of linvoseltamab in patients with relapsed or refractory multiple myeloma.